Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
about
The concept of treatment-free remission in chronic myeloid leukemiaChronic myeloid leukemia: reminiscences and dreamsReview of health-related quality of life data in multiple myeloma patients treated with novel agents.Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid LeukemiaEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry.Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Treatment recommendations for chronic myeloid leukemiaDefinition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Update on emerging treatments for chronic myeloid leukemia.Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine.First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Wage-subsidised employment as a result of permanently reduced work capacity in a nationwide cohort of patients diagnosed with haematological malignancies.Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib TherapyA critical history of chromic myeloid leukemiaEvaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burdenPrevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients.Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.Frames of Reference in Self-Reports of Health, Well-being, Fatigue, and Pain: A Qualitative ExaminationAchieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
P2860
Q26748733-56338FCC-85C3-4616-890A-B8060CF27306Q26748769-35D9AD68-43DE-4037-B5E8-346F59705927Q30650394-E280F6C9-8499-4338-BABB-CBB39A7084F5Q33433457-1D89342E-0BCB-41C7-966B-4F838696A6FAQ36880864-5E2D3832-3CA4-433A-8F1D-62EA555B8F05Q37026032-E097F8CF-8CEF-43B7-9E8E-212C73467FF0Q37666847-49CAEADD-2068-4AAA-84D9-0C58CF4E93FEQ37676310-C72668F8-030B-42F3-A22F-D858B26D3583Q37682689-1BBB6C7A-94B1-4A53-8AE4-939F7A08779EQ38181112-15D45A64-F9FE-4A2D-91D8-37FD5497D791Q38199143-8B4216AE-079D-4E48-8FBE-B3D78BD48AC1Q38397515-35C60233-308C-4F7F-95EF-0F704702D70BQ38557421-2C649771-D6D3-421A-A2CC-6A0A4A0644DDQ38620872-6B441FE0-CB1B-41E8-A4F2-682E7BE138B8Q38934423-55831810-464F-4C78-BBDC-C59647457D69Q40346616-AA9553B2-6C08-43E7-A3D3-5A4D69364DC6Q41264367-1937B63B-06B9-42F2-B03B-9B212EE2F86AQ41601810-B9DC948E-F55C-40C8-89D2-4B27FDF33D46Q41877378-B1A8C0E8-19AC-4E10-9DB1-54B40386354AQ42395994-63878055-828D-46FC-9735-4AAD597DD68AQ42633004-4E33C057-0DF7-4AF9-9B10-50F60301E0CFQ43984339-5CB02DFF-6328-4A2B-A9E3-5F862D500B8CQ47551814-A4E6C12C-E835-4B15-B9EB-553BF5784D6BQ47795207-A5416492-6371-48BD-84F0-312DB47FDD6FQ48082559-A50037F6-25EF-4B31-BD11-D5AB4919D4C4Q48170931-295A2D88-D7FF-4E0A-A946-2942333E0A89Q48778777-58EE7C8B-3244-4961-8ABA-D5B42FA6A1BCQ50457803-C4B37DD8-5F26-40FD-A186-316B720BB282Q54222671-ED118D35-3A2B-45C6-8229-E1C44970D98CQ54981978-1D370D31-69EE-4308-8106-C05E89F9D1DAQ57822554-4D88BDE0-09F4-4077-98E2-7A8C8EDDF76AQ58801283-A1121C4F-9D97-4AAE-AE17-F3C026B7D5A9
P2860
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Chronic fatigue is the most im ...... atients treated with imatinib.
@en
Chronic fatigue is the most im ...... atients treated with imatinib.
@nl
type
label
Chronic fatigue is the most im ...... atients treated with imatinib.
@en
Chronic fatigue is the most im ...... atients treated with imatinib.
@nl
prefLabel
Chronic fatigue is the most im ...... atients treated with imatinib.
@en
Chronic fatigue is the most im ...... atients treated with imatinib.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Chronic fatigue is the most im ...... atients treated with imatinib.
@en
P2093
A Rambaldi
F Efficace
F Mandelli
G L Deliliers
P2860
P2888
P304
P356
10.1038/LEU.2013.51
P577
2013-02-18T00:00:00Z
P6179
1030777154